← FDA DRUG APPROVALS

FDA ANDA · ANDA202054

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALETAE

ddorzolamide hydrochloride timolol maleate

Sponsor: REGCON HOLDINGS

APPLICATION
ANDA202054
TYPE
ANDA
ORIGINAL APPROVAL
2014-09-03
LATEST ACTION
2024-02-20
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Prescription

Products

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATEPrescription
DORZOLAMIDE HYDROCHLORIDE EQ 2% BASE, TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS · OPHTHALMIC

Approval history

2024-02-20Labeling · Supplement 7 · standardAP
2021-02-10Labeling · Supplement 2 · standardAP
2014-09-03Not Applicable · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →